Want to see TSE:ADK full AI Analyst Report?
ADK Stock Chart & Stats
C$0.41
C$0.01(4.35%)
At close: 4:00 PM EDT
C$0.41
C$0.01(4.35%)
Day’s Range― - ―
52-Week RangeC$0.18 - C$0.53
Previous CloseN/A
Volume130.25K
Average Volume (3M)290.25K
Market Cap
C$57.20M
Enterprise ValueC$32.59
Total Cash (Recent Filing)C$1.93M
Total Debt (Recent Filing)C$1.40M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding120,412,550
10 Day Avg. Volume239,170
30 Day Avg. Volume290,250
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)43.19
Price to Sales (P/S)453.09
P/FCF Ratio-7.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diagnostic Imaging FocusThe company operates in medical imaging and decision-support, addressing disease detection and assessment through technology. A specialized diagnostic platform can support repeatable solutions and potential operating leverage if adoption and commercialization improve over the medium term.
Positive Equity PositionDiagnos reported positive equity in the latest year after prior periods of negative equity, indicating some improvement in its capital position. The asset base provides a foundation for continued operations, although its durability depends on reducing losses and cash consumption.
Reported EPS ImprovementReported EPS growth provides a limited positive signal that per-share performance improved during the measured period. However, because the company remains deeply unprofitable, this does not establish earnings strength; sustained improvement would be needed to make the trend durable.
Bears Say
Sharp Revenue ContractionThe steep decline in revenue indicates shrinking commercial scale and weak business momentum. Lower sales reduce the company’s ability to absorb fixed operating costs, fund product development, and build a path toward breakeven, making recovery dependent on renewed customer adoption or commercialization.
Persistent UnprofitabilityLarge and recurring losses show that the current business model is not yet generating sustainable earnings. Continued unprofitability can erode equity, constrain investment in technology and commercialization, and increase dependence on external capital while management seeks to restore revenue scale.
Cash Burn And Fragile LeverageNegative operating and free cash flow mean the company is consuming cash rather than funding operations internally. Combined with debt near twice equity, this weakens financial flexibility and raises the likelihood that ongoing losses will require financing, potentially limiting strategic choices.
Diagnos News
ADK FAQ
What was Diagnos’s price range in the past 12 months?
Diagnos lowest stock price was C$0.17 and its highest was C$0.53 in the past 12 months.
What is Diagnos’s market cap?
Diagnos’s market cap is C$57.20M.
When is Diagnos’s upcoming earnings report date?
Diagnos’s upcoming earnings report date is Dec 01, 2026 which is in 71 days.
How were Diagnos’s earnings last quarter?
Diagnos released its earnings results on Jun 11, 2026. The company reported -C$0.01 earnings per share for the quarter.
Is Diagnos overvalued?
According to Wall Street analysts Diagnos’s price is currently Overvalued.
Does Diagnos pay dividends?
Diagnos does not currently pay dividends.
What is Diagnos’s EPS estimate?
Diagnos’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Diagnos have?
Diagnos has 120,412,550 shares outstanding.
What happened to Diagnos’s price movement after its last earnings report?
Diagnos reported an EPS of -C$0.01 in its last earnings report. Following the earnings report the stock price went down -3%.
Which hedge fund is a major shareholder of Diagnos?
Currently, no hedge funds are holding shares in TSE:ADK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Diagnos Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-34.26%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Diagnos
DIAGNOS Inc. is a technology firm that delivers software-based services across a broad international footprint, encompassing Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. A significant portion of its operations focuses on healthcare, where it provides Computer Assisted Retina Analysis (CARA). This advanced web-based platform is designed to support medical professionals in the early detection of diabetic retinopathy. It also empowers eye care specialists by enabling clear visualization of both standard retinal features and any pathological changes. Beyond its healthcare offerings, DIAGNOS Inc. extends its expertise through consulting services, specializing in the fields of data analytics and artificial intelligence (AI). Established in 1998, the company maintains its corporate headquarters in Brossard, Canada.
Technical Analysis
Rocket Doctor AI
―
Comprehensive Healthcare Systems Inc
―
UniDoc Health Corp
―
PanGenomic Health, Inc. Class A
―
DiagnaMed Holdings Corp.
―